{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T17:15:56Z","timestamp":1723223756551},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,11,1]]},"DOI":"10.2169\/internalmedicine.7028-21","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T22:08:35Z","timestamp":1621634915000},"page":"3441-3445","source":"Crossref","is-referenced-by-count":3,"title":["Sofosbuvir\/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir\/Pibrentasvir Therapy Failed"],"prefix":"10.2169","volume":"60","author":[{"given":"Ayami","family":"Nonomura","sequence":"first","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang","family":"Hai","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuzo","family":"Kozuka","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet 394: 1451-1466, 2019.","DOI":"10.1016\/S0140-6736(19)32320-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ikeda H, Watanabe T, Atsukawa M, et al. Evaluation of 8-week glecaprevir\/pibrentasvir treatment in direct-acting antiviral-na\u00efve noncirrhotic HCV genotype 1 and 2 infected patients in a real-world setting in Japan. J Viral Hepat 26: 1266-1275, 2019.","DOI":"10.1111\/jvh.13170"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study. Hepatol Res 49: 617-626, 2019.","DOI":"10.1111\/hepr.13328"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Uemura H, Uchida Y, Kouyama JI, et al. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol 54: 459-470, 2019.","DOI":"10.1007\/s00535-018-01543-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res 50: 791-816, 2020.","DOI":"10.1111\/hepr.13503"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Osawa M, Imamura M, Teraoka Y, et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 54: 291-296, 2019.","DOI":"10.1007\/s00535-018-1520-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tamori A, Inoue K, Kagawa T, Takaguchi K, et al. Intention-to-treat assessment of glecaprevir+pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. Hepatol Res 49: 1365-1373, 2019.","DOI":"10.1111\/hepr.13410"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C Virus Infection. Clin Infect Dis 67: 1477-1492, 2018.","DOI":"10.1093\/cid\/ciy585"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol 73: 1170-1218, 2020.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Kamae I, Kumada H, Kobayashi M, et al. Epidemiology, treatment, and health economics of Hepatitis C in Japan (Review). Kanzo 55: 589-603, 2014 (in Japanese, Abstract in English).","DOI":"10.2957\/kanzo.55.589"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takaki S, Imamura M, Yamaguchi S, et al. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol 13: 1233-1238, 2020.","DOI":"10.1007\/s12328-020-01182-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12: 356-367, 2018.","DOI":"10.1007\/s12072-018-9878-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sezaki H, Suzuki F, Hosaka T, et al. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections. J Gastroenterol 54: 916-927, 2019.","DOI":"10.1007\/s00535-019-01575-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nozaki A, Atsukawa M, Kondo C, et al. The effectiveness and safety of glecaprevir\/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int 14: 225-238, 2020.","DOI":"10.1007\/s12072-020-10019-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Singh AD, Maitra S, Singh N, et al. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 51: 490-504, 2020.","DOI":"10.1111\/apt.15633"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol 5: 839-849, 2020.","DOI":"10.1016\/S2468-1253(20)30086-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Krishnan P, Pilot-Matias T, Schnell G, et al. Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials. Antimicrob Agents Chemother 62: e01249-18, 2018.","DOI":"10.1128\/AAC.01249-18"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Esteban R, Pineda JA, Calleja JL, et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology 155: 1120-1127, 2018.","DOI":"10.1053\/j.gastro.2018.06.042"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology 66: 1083-1089, 2017.","DOI":"10.1002\/hep.29256"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7028-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T03:19:45Z","timestamp":1636168785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/21\/60_7028-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":19,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7028-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"7028-21"}}